NGT BioPharma Consultants understands the scientific and regulatory challenges companies face evaluating Late Discovery drug candidates and advancing them through nonclinical and clinic development. We work collaboratively with our clients to efficiently support and integrate the multidisciplinary evaluations required to characterize key drug properties, including pharmacology, safety toxicology, pharmacokinetics, and CMC attributes enabling progression into the clinic and ultimate market approval. We understand these critical interdependencies and will leverage our collective expertise and extensive experience to develop nonclinical plans to support a drug candidate’s proposed clinical indication and clinical development plan.